九芝堂(000989) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥913,370,019.78, representing a 10.34% increase compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥50,782,171.26, a significant increase of 64.08% year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥43,405,329.86, reflecting a 104.71% increase compared to the same period last year[3] - The company's basic earnings per share for Q3 2021 was ¥0.0595, up 61.68% year-over-year[3] - The company's total revenue for the first nine months of 2021 was ¥2,991,687,263.36, an increase of 12.44% year-over-year[3] - Total operating revenue for the period reached ¥2,991,687,263.36, an increase of 12.42% compared to ¥2,660,773,853.06 in the previous period[26] - Net profit for the period was ¥267,989,953.45, representing a 18.76% increase from ¥225,559,279.01 in the same period last year[29] - Earnings per share (EPS) for the period was ¥0.3165, compared to ¥0.2715 in the previous period, reflecting a growth of 16.00%[32] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥5,315,622,336.04, which is a 4.81% increase from the end of the previous year[3] - The total assets of the company reached approximately ¥5.32 billion as of September 30, 2021, compared to ¥5.07 billion at the end of 2020[19] - The total liabilities increased to ¥1,357,389,476.07, up from ¥1,146,085,261.02, indicating a growth of 18.38%[25] - The total equity attributable to shareholders of the parent company was ¥3,957,084,041.79, slightly up from ¥3,922,517,553.92[25] - The total assets reached ¥5,315,622,336.04, an increase from ¥5,071,508,340.80, reflecting a growth of 4.81%[25] - Current liabilities reached ¥1,075,790,413.12, remaining unchanged from the previous period[45] - Total liabilities were ¥1,146,085,261.02, down by ¥116,567,946.24 compared to the previous period[45] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥437,795,122.77, showing a decrease of 11.19% compared to the previous year[3] - Operating cash inflow for the current period reached ¥3,089,951,401.48, an increase of 7.9% from ¥2,863,051,945.68 in the previous period[33] - Net cash flow from operating activities was ¥437,795,122.77, down 11.2% from ¥492,939,861.32 year-over-year[36] - Cash inflow from investment activities totaled ¥2,848,621,763.01, a decrease of 22.1% compared to ¥3,656,267,683.98 in the previous period[36] - Net cash flow from investment activities was -¥527,184,364.41, contrasting with a positive cash flow of ¥294,552,214.60 in the previous year[36] - Cash outflow from financing activities amounted to ¥477,542,407.25, compared to ¥337,107,003.40 in the previous period[36] - The net increase in cash and cash equivalents was -¥486,931,648.89, compared to an increase of ¥552,314,211.57 in the previous year[36] - The ending balance of cash and cash equivalents was ¥307,851,025.97, down from ¥849,745,074.74 in the previous period[36] Shareholder Information - The total number of common shareholders at the end of the reporting period was 48,452, with the top ten shareholders holding a combined 31.52% of shares[11] - Li Zhengguo, a domestic individual, holds 31.52% of shares, amounting to 274,008,371 shares, with 254,402,140 shares pledged[11] - Heilongjiang Cheneng Gongda Venture Capital Co., Ltd. holds 19.48% of shares, totaling 169,348,487 shares[11] Investments and R&D - The company experienced a 544.75% increase in construction in progress, totaling ¥11,250.81 million, due to investments in the health industry park project[7] - Research and development expenses for the period were ¥79,930,348.22, a slight increase from ¥77,713,153.29 in the previous period[26] - The company received approval from the FDA for clinical trials of its innovative drug YB209 in the U.S.[15] - Seven traditional Chinese medicine products received import and operating licenses from Brazil's ANVISA[15] Financial Standards and Changes - The company's financial expenses increased by 481.39% to ¥335.66 million, primarily due to the implementation of new leasing standards[9] - The company has implemented new leasing standards effective from January 1, 2021, impacting the recognition of right-of-use assets and lease liabilities[45]